AbCellera IPO Presentation Deck

CASE STUDY: COVID-19 BAMLANIVIMAB AUTHORIZED FOR EMERGENCY USE IN THE U.S. & CANADA. YLOSTIPANO bamlanivimab injection 700 mg/20 ml (35 mg/ml) NDC:0002-7910-01 bamlanivimab injection 700 mg/20 mL (35 mg/mL) For intravenous infusion Only Must diute before use Single-Dose Via Discard Unused Partion For use under Emergency Use Authorization (EUA) Lilly AbCellera Based on Phase 2 monotherapy trial results 72% risk reduction in hospitalizations compared to placebo in patients recently diagnosed with mild-to- moderate COVID-19

View entire presentation